

Special Issue

New Insights in Radiotherapy: Bridging Radiobiology and Oncology

Message from the Guest Editors

Radiotherapy has long been used to treat or alleviate various types of cancer. This Special Issue aims to highlight recent advances in the evaluation of physical and biological factors that lead to radiation-induced radiobiological effects, including the immunological effects of radiotherapy, the normal tissue-sparing effect enhanced by FLASH radiotherapy, the bystander effect via synaptic transmission, and radiation-induced lethality on different types of cancers at the organismic, tissue, and cellular levels. Topics of interest include the association of radiation beam quality with the abscopal effect through the activation of the systemic immune response and immunogenic cell death, tissue-specific responses to different irradiation regimens, parameters in mediating radiation effects to non-irradiated neurons, and the modulatory effect of LET on the radiation-induced lethality of different types of cancers. We invite contributions that provide insights into novel biological pathways, biophysical mechanisms, radioprotection and radiosensitization strategies, and regulatory considerations to ensure the appropriateness and safety of medical radiation applications.

Guest Editors

Dr. Yuan-Hao Lee

Department of Biomedical Imaging and Radiological Science, China Medical University, Taichung 40402, Taiwan

Dr. I-Tsang Chiang

1. Department of Medical Imaging and Radiologic Sciences, Central Taiwan University of Science and Technology, Taichung, Taiwan
2. Department of Radiation Oncology, Show Chwan Memorial Hospital, Changhua, Taiwan
3. Research Assistant Center, Show Chwan Memorial Hospital, Changhua, Taiwan

Deadline for manuscript submissions

30 November 2025



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/237968

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2024).